Inactive Instrument

CinCor Pharma, Inc.

Equities

CINC

US17240Y1091

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AstraZeneca Completes $1.8 Billion Acquisition of CinCor Pharma to Boost Cardiorenal Portfolio MT
AstraZeneca closes CinCor buy; Enhertu wins Chinese approval AN
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from NASDAQ Composite Index CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from S&P Global BMI Index CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from S&P TMI Index CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from NASDAQ Biotechnology Index CI
Astrazeneca Finance And Holdings Inc. completed the acquisition of CinCor Pharma, Inc. from a group of shareholders. CI
CinCor Pharma, Inc. Announces Completion of End-of-Phase 2 Meeting with U.S. Food and Drug Administration on Anticipated Phase 3 Program for Baxdrostat in Hypertension CI
AstraZeneca Initiates Tender Offer For $2 Billion CinCor Takeover MT
ADRs End Higher; AstraZeneca, Barclays Trade Actively DJ
Biotech IPO Window to Reopen in 2023 Following Muted Activity in 2022, Oppenheimer Says MT
AstraZeneca Unit Starts Tender Offer to Purchase CinCor Pharma MT
North American Morning Briefing : Big Day For Bank -2- DJ
Barclays Downgrades CinCor Pharma to Equal-Weight Rating From Overweight, Adjusts Price Target to $31 From $22 MT
Morgan Stanley Adjusts Price Target on CinCor Pharma to $30 From $22, Maintains Equal-Weight Rating MT
MarketScreener's World Press Review: January 10 Our Logo
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup DJ
Sector Update: Health Care Stocks Largely Struggle Monday MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Struggling to Begin New Week MT
FTSE 100 Closed Up Boosted by China Reopening DJ
European Markets Advance as Germany Eases Recession Fears MT
Global markets live: Alibaba, Qiagen, Macy's, Oracle, Chevron... Our Logo
The return of optimism Our Logo
Sterling to Rally if UK GDP Data Beat Forecasts DJ
Chart CinCor Pharma, Inc.
More charts
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). It also exploring its utility in ameliorating complications of CKD. It is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.
More about the company
  1. Stock
  2. Equities
  3. Stock CinCor Pharma, Inc. - Nasdaq
  4. News CinCor Pharma, Inc.
  5. CinCor Pharma Doses First Patient in Chronic Kidney Disease Treatment Phase 2 Trial; Shares Rise